Covalon Receives FDA Approval for ColActive Collagen Scaffold

Covalon Technologies, a medical biosystems company that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings, announced that it has received FDA approval for its collagen scaffold ColActive as a wound dressing.

The FDA approval allows Covalon to commence the launch of ColActive and begin to process orders for the product. The company has an exclusive distribution agreement with Hartmann-Conco to distribute Covalon collagen wound dressings under the brand name ColActive in the U.S.

"This is an extremely important milestone for Covalon to receive this FDA approval," said Covalon CEO Frank DiCosmo. "The company is now revenue producing and we look forward to working with our partner Hartmann-Conco to maximize the potential of this product."